CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Yigansan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03564132
NCT03564132Phase 2Completed

A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's Disorder

China Medical University Hospital·interventional·Posted Jun 20, 2018·Updated Apr 27, 2023

In Brief

A Phase 2 clinical trial evaluating Yigansan and Placebo for Tourette Disorder and Tic Disorders. Completed, enrolled 38 participants across 1 site.

Detailed Summary

Yigansan was used in Ming dynasty by Xue Kai as a remedy for restlessness and agitation in children. We expect that the total YGTSS scores of Yigansan-treated subjects will be significantly reduced compared to that of placebo-treated subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 20, 2018
Enrollment StartJun 16, 2018
Primary CompletionAug 15, 2020
Study CompletionAug 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.0 years ago

Interventions

Yigansandrug

Yigansan granules

Placebodrug

One-tenth concentration of Yigansan manufactured to mimic Yigansan granules